GeneReach Biotechnology Cash Flow Quality Index
GeneReach Biotechnology cash flow quality index. GeneReach Biotechnology (4171) has a Cash Flow Quality Index of 4.33x as of December 2025. Operating cash flow of NT$12.05 Million exceeds net income of NT$2.79 Million, indicating high earnings quality where cash backs reported profits. See GeneReach Biotechnology (4171) flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of GeneReach Biotechnology (2018–2022)
Cash flow quality index of GeneReach Biotechnology from 2018 to 2022. Historical Cash Flow Quality Index for GeneReach Biotechnology across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 4171 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
GeneReach Biotechnology Cash Flow Quality Index by Year (2018–2022)
GeneReach Biotechnology cash flow quality index by year from 2018 to 2022. Year-by-year earnings quality comparison for GeneReach Biotechnology. For the full cash flow conversion analysis, see GeneReach Biotechnology (4171) cash flow conversion.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.62x | NT$357.63 Million | NT$221.34 Million | ▲ +117.3% |
| 2021 | 0.74x | NT$348.99 Million | NT$469.37 Million | ▲ +48.4% |
| 2020 | 0.50x | NT$169.82 Million | NT$338.94 Million | ▲ +445.5% |
| 2019 | -0.15x | NT$-11.19 Million | NT$77.18 Million | ▼ -172.1% |
| 2018 | 0.20x | NT$5.74 Million | NT$28.57 Million | — |